SeqLL, Inc. Overview
Pro stress-test →SeqLL is a technology company providing life sciences instrumentation and research services that leverages its True Single Molecule Sequencing (tSMS) platform to empower scientists and researchers with improved genetic tools to better understand molecular mechanisms of disease. The company operates at the intersection of genomics research and precision medicine, offering proprietary sequencing technologies unavailable through conventional platforms.
Strategic Profile
Pro stress-test →Founded in 2013, SeqLL delivers true Single Molecule Sequencing (tSMS) technology to research and healthcare organizations, uniquely positioned to address gaps left by standard sequencing technologies in RNA transcriptome analysis and specialty DNA analysis. The company is advancing application development for early detection of cancer and other diseases alongside technology advancement in rapid screening and sequencing methodologies.
Competitive Landscape
Pro stress-test →Top competitors include Strand Life Sciences, Tessera Therapeutics, and BGI. SeqLL competes in the broader genomics sequencing market dominated by Illumina, 10x Genomics, and PacBio, which offer mature, well-funded platforms with established customer bases. SeqLL's differentiation lies in single-molecule direct RNA sequencing without PCR amplification, targeting researchers seeking alternative methodologies for specialized applications. However, the company's micro-scale operations and minimal revenue generation limit competitive positioning relative to well-established sequencing infrastructure providers.
Industry Context
SeqLL, Inc. operates in Next-generation sequencing platforms.
Key facts
Founded: 2013 · Headquarters: Woburn, MA, US · Employees: 3–7 · Revenue: $330,000 (2026) · Market cap: N/A